PMID- 8800741
OWN - NLM
STAT- MEDLINE
DCOM- 19961001
LR  - 20181130
IS  - 1043-0342 (Print)
IS  - 1043-0342 (Linking)
VI  - 7
IP  - 4
DP  - 1996 Mar 1
TI  - Adenovirus-mediated interferon-gamma transfer inhibits growth of transplanted 
      HTLV-1 Tax tumors in mice.
PG  - 471-7
AB  - Human T cell leukemia virus type 1 (HTLV-1) causes adult T cell leukemia (ATL), 
      and the virus-encoded trans-activator, Tax, plays an important role in T cell 
      transformation. In the HTLV-1 long terminal repeat (LTR)-Tax transgenic mouse 
      model, Tax expression causes fibroblastic tumors. A tumor-derived cell line (B 
      line) obtained from an explant of a Tax-transformed tumor, was established. This 
      line expresses high levels of many cytokines as a consequence of Tax activation. 
      However, the tumors are not immunogenic when transplanted into syngeneic mice. 
      Because B line cells do not express the immunogenic cytokine interferon-gamma 
      (IFN-gamma), a replication-defective adenoviral vector was used to deliver the 
      IFN-gamma gene to tumor cells. The recombinant IFN-gamma adenovirus 
      (IFN-gamma/Ad) can efficiently infect B line cells, resulting in high levels of 
      IFN-gamma expression and secretion. Local secretion of IFN-gamma from B line 
      cells caused both CD(4+)- and CD(8+)-positive T cell infiltration, and completely 
      inhibited local tumor development in transplanted mice. Immunization with these 
      cells significantly delayed tumor development after subsequent challenges of 
      parental tumor cells. Expression of IFN-gamma in B cells also partially inhibited 
      the highly expressed immune suppressive cytokine, transforming growth factor-beta 
      1 (TGF-beta 1). This system provides us with a valuable tumor immune therapy 
      model to evaluate the effects of cytokines in induction or inhibition of specific 
      antitumor immunity.
FAU - Xu, X
AU  - Xu X
AD  - Department of Molecular and Experimental Medicine, Scripps Research Institue, La 
      Jolla, CA 92037, USA.
FAU - Dai, Y
AU  - Dai Y
FAU - Heidenreich, O
AU  - Heidenreich O
FAU - Nerenberg, M I
AU  - Nerenberg MI
LA  - eng
GR  - CA50234/CA/NCI NIH HHS/United States
GR  - NS12428/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Hum Gene Ther
JT  - Human gene therapy
JID - 9008950
RN  - 0 (Gene Products, tax)
RN  - 0 (Transforming Growth Factor beta)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adenoviruses, Human/*genetics
MH  - Animals
MH  - B-Lymphocytes/cytology
MH  - Down-Regulation
MH  - Fibrosarcoma/*therapy
MH  - Gene Expression
MH  - Gene Products, tax/genetics/metabolism
MH  - Gene Transfer Techniques
MH  - *Genetic Therapy
MH  - Genetic Vectors
MH  - *Human T-lymphotropic virus 1
MH  - Humans
MH  - Interferon-gamma/*genetics/metabolism/therapeutic use
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasm Transplantation
MH  - Transforming Growth Factor beta/genetics/metabolism
MH  - Tumor Cells, Cultured
MH  - Vaccination
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 10.1089/hum.1996.7.4-471 [doi]
PST - ppublish
SO  - Hum Gene Ther. 1996 Mar 1;7(4):471-7. doi: 10.1089/hum.1996.7.4-471.